In ER+ early-stage breast cancer
The only robust, validated tool to help with clinical decision-making for extended endocrine treatment
- Predictive for likelihood of benefit from extended endocrine therapy
- Prognostic for risk of late distant recurrence
Actionable genomic information for accurate diagnosis for metastatic patients with diagnostic ambiguity
- CancerTYPE ID is a most validated gene expression-based assay to help achieve an accurate diagnosis